Shekhar, A.* ; Di Lucrezia, R.* ; Jerye, K.* ; Korotkov, V.S.* ; Harmrolfs, K.* ; Rox, K.* ; Weich, H.A.* ; Ghai, I.* ; Delhommel, F. ; Becher, I.* ; Degenhart, C.* ; Fansa, E.* ; Unger, A.* ; Habenberger, P.* ; Klebl, B.* ; Lukat, P.* ; Schmelz, S.* ; Henke, S.* ; Borgert, S.* ; Lang, J.C.* ; Sasse, F.* ; Diestel, R.* ; Richter, C.* ; Schneider-Daum, N.* ; Hinkelmann, B.* ; Niemz, J.* ; Lehr, C.M.* ; Jänsch, L.* ; Huehn, J.* ; Alm, R.* ; Savitski, M.M.* ; Welte, T.* ; Hesterkamp, T.* ; Sattler, M. ; Winterhalter, M.* ; Blankenfeldt, W.* ; Medina, E.* ; Bilitewski, U.* ; Dinkel, K.* ; Brönstrup, M.*
Highly potent quinoxalinediones inhibit α-hemolysin and ameliorate Staphylococcus aureus lung infections.
Cell Host Microbe 33, 560-572.e21 (2025)
Hospital-acquired pneumonia caused by Staphylococcus aureus is associated with patient morbidity and mortality, despite adequate antibiotic therapy. This illustrates the need for treatments beyond antibiotics. The pore-forming heptameric toxin α-hemolysin (Hla) is a major pathogenicity factor of S. aureus and a clinically validated target. We identify quinoxalinediones (QDS) as highly potent Hla inhibitors, conferring protection against the hallmarks of Hla-induced pathogenicity such as Ca2+ influx, cytotoxicity, hemolysis, and monolayer destruction. The effects were exerted across major Hla subtypes in all relevant cell types. QDS prevented the formation of functional pores by interacting with Hla near the phospholipid-binding site. The QDS analog, H052, was active in mouse models of S. aureus lung infections, when administered prophylactically or therapeutically, either as monotherapy or when given in combination with the antibiotic linezolid. The study provides evidence that complex bacterial toxins can be targeted in vivo by drug-like small molecules.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
Publication type
Article: Journal article
Document type
Scientific Article
Thesis type
Editors
Keywords
Staphylococcus Aureus ; Antibacterials ; Drug Discovery ; Lung Infections ; Mechanism Of Action ; Toxin Inhibition ; Virulence Inhibitors; Alpha-hemolysin; Monoclonal-antibody; Escherichia-coli; Nmr-spectroscopy; Pneumonia; Toxin; Expression; Virulence; Prevention; Strategies
Keywords plus
Language
english
Publication Year
2025
Prepublished in Year
0
HGF-reported in Year
2025
ISSN (print) / ISBN
1931-3128
e-ISSN
1934-6069
ISBN
Book Volume Title
Conference Title
Conference Date
Conference Location
Proceedings Title
Quellenangaben
Volume: 33,
Issue: 4,
Pages: 560-572.e21
Article Number: ,
Supplement: ,
Series
Publisher
Elsevier
Publishing Place
50 Hampshire St, Floor 5, Cambridge, Ma 02139 Usa
Day of Oral Examination
0000-00-00
Advisor
Referee
Examiner
Topic
University
University place
Faculty
Publication date
0000-00-00
Application date
0000-00-00
Patent owner
Further owners
Application country
Patent priority
Reviewing status
Peer reviewed
POF-Topic(s)
30203 - Molecular Targets and Therapies
Research field(s)
Enabling and Novel Technologies
PSP Element(s)
G-503000-001
Grants
Drug Discovery and Cheminformatics for New Anti-Infectives" (iCA)
German Center for Infection Research
HZI pre-4D fund
Helmholtz Validation Fund
Copyright
Erfassungsdatum
2025-05-09